Outcome of COVID-19 Patients Presented with Gastrointestinal and Hepatic Manifestations
Table 2
Association between demographic characteristics, clinical characteristics, and presence of gastrointestinal symptoms at admission.
Characteristics
Patients with GI symptoms ()
Patients without GI symptoms ()
Overall ()
value
Demographic characteristics
Age in yrs ()
0.827
Sex: female %
21 (45.7%)
84 (43.1%)
0.751
BMI ()
0.970
Preexisting GI diseases - %
1 (2.2%)
4 (2%)
5 (2.1%)
0.849
Preexisting liver diseases-%
3 (6.6%)
10 (5.1%)
13 (5.4%)
0.691
Other comorbidities - %
24 (52.2%)
103 (52.8%)
127 (52.7%)
0.937
Complete vaccination - %
9 (19.6%)
29 (14.9%)
38 (15.8%)
0.691
Days of disease onset at the time admission ()
0.023
Clinical characteristics ()
WCC (×109/L)
0.978
Lymphocyte (×109/L)
0.801
Platelet (×109/L)
0.178
Total bilirubin (mg/dL)
0.063
ALT (U/L)
0.172
AST (U/L)
0.244
ALP (U/L)
0.460
Albumin (mg/dL)
0.346
INR
0.595
Treatment at hospital:(%)
AV alone
4 (8.7%)
15 (7.7%)
CS alone
10 (21.7%)
40 (20.5%)
AV and CS combined
15 (32.6%)
44 (22.6%)
CS and IM combined
NIL
2 (1%)
AV, CS, and IM combined
NIL
3 (1.5%)
Data are expressed as mean (SD) or (%). BMI: body mass index; GI: gastrointestinal; WCC: white cell count; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; INR: international normalized ratio; SD: standard deviation; AV: antiviral; CS: corticosteroid; IM: immunomodulator.
